Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 23, 2025
Drug Development
Linda Jo Van Eldik, Saktimayee M Roy, Ottavio Arancio, et al.
Cells
|
February 12, 2026
The Highly Selective 5-HT<sub>2B</sub> Receptor Antagonist MW073 Mitigates Aggressive Behavior in an Alzheimer's Disease Mouse Model
Erica Acquarone, Saktimayee M Roy, Agnieszka Staniszewski, et al.
Journal of Alzheimer'S Disease : JAD
|
April 5, 2024
The 5HT2b Receptor in Alzheimer's Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction
Erica Acquarone, Elentina K Argyrousi, Ottavio Arancio, et al.
Journal of Neuroinflammation
|
April 7, 2017
Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes
Zhengqiu Zhou, Adam D Bachstetter, Claudia B Späni, et al.
Plos One
|
January 26, 2022
Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology
David J Braun, David K Powell, Christopher J McLouth, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
March 28, 2025
Optimized 5-HT<sub>2b</sub> inhibitors for neuropsychiatric syndromes with cognitive dysfunction
Saktimayee M Roy, Erica Acquarone, Elentina K Argyrousi, et al.
Journal of Medicinal Chemistry
|
July 17, 2020
Correction to "A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction"
Saktimayee M Roy, George Minasov, Ottavio Arancio, et al.
Journal of Medicinal Chemistry
|
April 13, 2019
A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction
Saktimayee M Roy, George Minasov, Ottavio Arancio, et al.
Alzheimer'S Research & Therapy
|
December 16, 2016
Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology
Nicole Maphis, Shanya Jiang, Guixiang Xu, et al.
Journal of Neuroinflammation
|
September 6, 2007
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model
Lenka Munoz, Hantamalala Ralay Ranaivo, Saktimayee M Roy, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 23, 2025
Drug Development
Linda Jo Van Eldik, Saktimayee M Roy, Ottavio Arancio, et al.
Cells
|
February 12, 2026
The Highly Selective 5-HT<sub>2B</sub> Receptor Antagonist MW073 Mitigates Aggressive Behavior in an Alzheimer's Disease Mouse Model
Erica Acquarone, Saktimayee M Roy, Agnieszka Staniszewski, et al.
Journal of Alzheimer'S Disease : JAD
|
April 5, 2024
The 5HT2b Receptor in Alzheimer's Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction
Erica Acquarone, Elentina K Argyrousi, Ottavio Arancio, et al.
Journal of Neuroinflammation
|
April 7, 2017
Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes
Zhengqiu Zhou, Adam D Bachstetter, Claudia B Späni, et al.
Plos One
|
January 26, 2022
Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology
David J Braun, David K Powell, Christopher J McLouth, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
March 28, 2025
Optimized 5-HT<sub>2b</sub> inhibitors for neuropsychiatric syndromes with cognitive dysfunction
Saktimayee M Roy, Erica Acquarone, Elentina K Argyrousi, et al.
Journal of Medicinal Chemistry
|
July 17, 2020
Correction to "A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction"
Saktimayee M Roy, George Minasov, Ottavio Arancio, et al.
Journal of Medicinal Chemistry
|
April 13, 2019
A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction
Saktimayee M Roy, George Minasov, Ottavio Arancio, et al.
Alzheimer'S Research & Therapy
|
December 16, 2016
Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology
Nicole Maphis, Shanya Jiang, Guixiang Xu, et al.
Journal of Neuroinflammation
|
September 6, 2007
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model
Lenka Munoz, Hantamalala Ralay Ranaivo, Saktimayee M Roy, et al.
Page
of 2